An interventional study of Sodium propionate and Placebo in CKD (Chronic Kidney Disease) Stage 5D, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Renal Insufficiency, Chronic with a site in Germany — 26 open to participants now, 43 under way, 19 of them phase 3. Renal Insufficiency, Chronic · Germany.
Among the 232 studies in Renal Insufficiency, Chronic with a site in Germany, this one is the 165th largest by planned enrollment of the 183 interventional ones that give a count, is one of 13 that started in 2024, is one of 31 with no phase, reaches primary completion later than 9 of the 42 other live ones, and was the 192nd registered.
3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →26 of the 232 studies in Renal Insufficiency, Chronic with a site in Germany are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Germany, United States, Argentina and 34 more countries
Ages 18+
Eli Lilly and Company · Sites in Germany, Argentina, Australia and 35 more countries
Ages 50+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Germany, United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 12 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 44 · Phase 3 80 · Phase 4 9
First in 2001; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 140 across the 183 interventional studies, 500 across the 49 observational. Of the 175 that completed or were terminated, 88 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 232 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 5 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
14 of the studies in Renal Insufficiency, Chronic with a site in Germany that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 14 to your calendar (.ics) → With an account.
Among the 232 studies in Renal Insufficiency, Chronic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pro-Kids is a multi-center, double-blind, randomized and placebo-controlled intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.
Chronic inflammation is a major risk factor of cardiovascular disease progression in CKD, irrespective of confounding comorbidities. Based on current knowledge, microbially-derived metabolites such as short chain fatty acids (SCFA) play an important role in the regulation of chronic inflammatory processes in CKD patients. Children with CKD are known to have reduced serum levels of the SCFA propionic acid (PA), as a consequence of both gut microbial dysbiosis and reduced fiber intake. In animal and human studies the impact of PA on function and abundance of regulatory T cells (Treg) has been demonstrated. Consequently, the investigators aim to normalize the PA serum levels by oral PA food supplementation in hemodialysis patients in order to mitigate chronic inflammation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The group which receives the PA as a dietary food supplement. A single capsule contains 500mg of sodiumpropionate, which is taken twice daily for 28 days.
Dietary Supplement: Sodium propionate
The control-group receives a placebo instead of propionate. The placebo contains maltodextrin and the same amount of sodium chloride as compared to the PA intervention. The placebo is taken twice per day for 28 days.
Other: Placebo
The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
Change in count of regulatory T-cells from baseline to week 4
Analysis of Treg counts in whole blood (absolute quantification) and peripheral blood mononuclear cells (PBMC; relative quantification) by flow cytometry.
Time frame: Baseline visit (week 0) in comparison to week 4
Propionic acid serum levels and targeted metabolomics
Analysis of PA serum levels and other microbially-derived metabolites by GC-MS and LC-MS
Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12
Immune cell phenotyping of peripheral blood mononuclear cells (PBMC)
Patients PBMC will be thawed and immune cells we be analyzed using multicolor flow cytometry and mass cytometry. By using a broad range of different antibodies combined in several panels the investigators will analyse distinct T cell subtypes including markers of activation, but also other immune cells (including B cells, dendritic cells, monocytes, natural killer cells). Data will reported in relation to parent populations (e.g. T heller cells in % of T cells).
Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12
T regulatory cell (Treg) suppression assay
The suppressive capacity of patients Treg will be analyzed by co-cultivation with conventional, stimulated T cells (Tconv) in different proportions (Treg:Tconv). The proliferation of Tconv will be reported.
Time frame: Baseline visit (week 0); Week 4
Single cell RNA sequencing of immune cells
Analysis of the transcriptome of immune cells using cellular indexing of transcriptomes and epitopes (CITEseq)
Time frame: Baseline visit (week 0); Week 4
Intestinal barrier function
Analysis of biomarkers for intestinal barrier function, such as sCD14, zonulin-1 and LPS
Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12
Taxonomy of the fecal microbiome
The taxonomy of the fecal microbiome will be anayzed using 16S RNA amplicon sequencing.
Time frame: Baseline visit (week 0); Week 4
Cardiovascular Phenotyping
Analysis of heart rate over time.
Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12
Cardiovascular Phenotyping
Analysis of blood pressure over time.
Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12
Cholesterol levels
Cholesterol levels will be assessed using standard clinical lab values.
Time frame: Baseline visit (week 0); Week 2; Week 4; Week 12
Ran from Jan 2024 to primary completion in Jul 2026, 29 months.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 29 months is above that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2025 → Jul 2026 and completion Apr 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium propionate
Renal Insufficiency, Chronic →
Charite University, Berlin, Germany →